DepoCyte

RSS

cytarabine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for DepoCyte has been withdrawn at the request of the marketing authorisation holder. 

This EPAR was last updated on 07/10/2019

Authorisation details

Product details
Name
DepoCyte
Agency product number
EMEA/H/C/000317
Active substance
cytarabine
International non-proprietary name (INN) or common name
cytarabine
Therapeutic area (MeSH)
Meningeal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01BC01
Publication details
Marketing-authorisation holder
Pacira Limited
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
11/07/2001
Contact address
3 Glory Park Avenue
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0DF
United Kingdom

Product information

26/06/2017 DepoCyte - EMEA/H/C/000317 - N/0059

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Assessment history

How useful was this page?

Add your rating